Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Naia Pharmaceuticals
George Town, Cayman Islands
- Ownership
- Private
- Employees
- ~10
- Development stage
- Other
01
Overview
Naia Pharmaceuticals was a clinical-stage biotechnology company that utilized a hub-and-spoke business model to develop a diverse portfolio of drugs for rare diseases and metabolic disorders. Its lead program was NAI-101, a long-acting GLP-2 analog for Short Bowel Syndrome that reached Phase 2 readiness. The company operated via specialized subsidiaries such as Naia Rare Diseases and Naia Liver, sourcing assets through global R&D arbitrage, but has been inactive since approximately 2017.
- Therapeutic areas
- EndocrinologyRare DiseasesGastroenterology
- Modalities
- PeptidesSmall molecule
- Industry
- Biotech
02
Partnerships
Cediprof
Beyond the preview
Go deeper on Naia Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Naia Pharmaceuticals.